About Minapharm:Minapharm Pharmaceuticals is a leading pharmaceutical company in Egypt and the Middle East and the largest end-to-end manufacturer of biological therapies in MEA with over 20 years of experience in cellular and bioprocess engineering. Headquartered in Cairo, Minapharm commercializes over 100 life-saving and life-enhancing products ranging from small molecules to complex bioengineered proteins and viral vectors, with an impressive immunotherapy pipeline. Together with its wholly-owned Berlin-based subsidiary, ProBioGen AG - a world-leading CDMO, Minapharm has established an integrated business model making it the only gene-to-market company in the region. Consolidating its international platform of intelligent biopharmaceutical technologies with the longstanding process development and manufacturing expertise in the MEA, Minapharm, together with ProBioGen, has incorporated MiGenTra GmbH headquartered in Berlin and manufacturing in Cairo, to enhance the accessibility to critical healthcare transforming medicines through product development and commercialization of Biosimilar mABs, Cell, and Gene Therapies and vaccines, at affordable prices in Egypt, and MEA.Our Values:· Diversity & Respect· Integrity & Accountability· Collaboration· Leadership & Empowerment· Innovation & Continuous LearningJob Summary:Leads all group-level financial reporting, consolidation, and technical accounting activities across all Minapharm entities. The role is the primary liaison between subsidiary finance teams, the Group Financial Controller, and external auditors (EY). It ensures full compliance with Egyptian Accounting Standards (EAS), IFRS where applicable, and all regulatory requirements, while maintaining a robust Oracle EBS-driven reporting environment. The role manages a full team covering reporting, consolidation, and tax specialists.Job duties & responsibilities:Financial Reporting & Consolidation:Lead preparation of standalone and consolidated financial statements for all Group entities under EAS and IFRS.Own the Group consolidation process including intercompany eliminations, foreign currency translation, and minority interest.Manage period-end close (monthly, quarterly, annual) ensuring accuracy, completeness, and timely reporting.Ensure accurate disclosure of accounting policies, significant judgments, and estimates in financial statements.Coordinate preparation of comparative statements and restatements under EAS No. 5 when required.2.Technical Accounting:Act as Group technical accounting authority; research and interpret complex EAS/IFRS standards and prepare formal position papers.Lead accounting treatment for non-routine transactions: business combinations, provisions, impairment, IFRS 16/EAS 20 leases, revenue recognition.Evaluate accounting and disclosure implications of subsequent events, contingent liabilities, and regulatory changes.Coordinate with external auditors (EY) on technical accounting matters and management representation letters.3.Audit Management:Serve as primary point of contact for external and internal auditors; manage the end-to-end audit lifecycle across all Group entities.Coordinate timely preparation and delivery of audit evidence packages, schedules, and reconciliations.Track, manage, and resolve all reviewer and auditor comments within agreed timelines.Oversee preparation of management representation letters and follow up on audit findings.4.Tax Reporting & Oversight:Supervise preparation and review of corporate income tax computations, deferred tax calculations, and provisions.Ensure proper disclosure of current and deferred tax balances under EAS No. 24.Liaise with tax team and external advisors to ensure timely filing and management of tax risks.5.Oracle EBS & Systems:Oversee integrity of financial data in Oracle EBS (GL, Fixed Assets, AP, AR) across all Group entities.Lead system-driven period-end close including account reconciliations, GL reviews, and intercompany matching.Collaborate with IT/ERP teams to develop and maintain reporting templates, COA structures, and consolidation mappings.6.Team Leadership:Lead, coach, and develop a high-performing team of senior accountants, reporting analysts, and tax specialists.Set clear objectives, conduct performance reviews, and identify training needs for direct reports.Foster a culture of accuracy, accountability, and continuous improvement within the finance function.Job requirements:Bachelor's degree in accounting, Finance, or related field .Master's degree in accounting, Finance, or MBA is a strong advantage.Minimum 10 years of progressive experience in financial reporting, consolidation, and technical accounting.At least 4 years in a managerial or supervisory capacity overseeing a reporting or accounting team.Professional Certifications:CPA (Certified Public Accountant) strongly preferred.ACCA — strongly preferred.CMA (Certified Management Accountant) is a plus.Experience within pharmaceutical, manufacturing, or FMCG sector is highly preferred.Hands-on experience managing external audits with Big 4 firms (EY, KPMG, Deloitte, PwC) is essential.Technical Knowledge:Deep knowledge of Egyptian Accounting Standards (EAS) and IFRS (IFRS 9, 15, 16, IAS 12, 36, 37).Strong understanding of group consolidation mechanics including intercompany, FX translation, and equity accounting.Proficiency in Oracle EBS (GL and related sub-ledgers) — mandatory.Advanced Microsoft Excel skills; familiarity with Egyptian corporate tax law.Benefits· Transportation provided· Medical Insurance· Life Insurance· Profit share
Minapharm Pharmaceuticals is an Egyptian pharmaceutical company manufacturing and marketing prescription medicines across therapeutic areas including immunology, oncology, neuroscience, and infectious disease. The company also operates biotechnology research and contract manufacturing services.
What you should know
Comprehensive Bioengineered Medicines: Employs over 1,400 people and manages a product portfolio of life-saving medicines ranging from small molecules to complex bioengineered proteins
Biotech Powerhouse: Operates as a leader in regional biotechnology through its German subsidiary ProBioGen, providing advanced cell line development and genetic engineering
Phase 1 Approval: Achieved a significant milestone in 2023 by receiving regulatory approval from Germany's Paul-Ehrlich Institute for a phase 1 clinical trial of its Adalimumab biosimilar